TC Biopharm (Holdings) Plc (TCBP)
| Previous close | 5.92 |
| Open | 6.10 |
| Bid | 6.27 x 100 |
| Ask | 7.07 x 100 |
| Day's range | 5.74 - 6.87 |
| 52-week range | 2.11 - 1,140.00 |
| Volume | |
| Avg. volume | 210,630 |
| Market cap | 3.808M |
| Beta (5Y monthly) | 0.11 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -203.22 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireTCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered into a sponsored research agreement with Carnegie Mellon University to explore the potential use of artificial intelligence to optimize the patient screening process.
PR NewswireTCBP Announces Site Opening of Guys and St. Thomas Hospital
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced new site opening of Guys and St. Thomas Hospital in the ACHIEVE UK Trial.
- PR Newswire
TCBP to Present at the 2024 ThinkEquity Conference in NYC
TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that Chief Executive Officer Bryan Kobel has been invited to present at the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York City.
